Translational Immunotherapy of Brain Tumors
Immune Constitution of Patients with Brain Tumors
Publication
, Chapter
Berry-Candelario, J; Farber, SH; Fecci, PE
March 2, 2017
Immune deficiencies in patients with glioblastoma (GBM) are not a new discovery. Researchers have been perplexed and challenged by impairments to immunity in the context of GBM dating back to the 1970s. As immunotherapy has become both more studied and more developed, increasing evidence has highlighted factors ranging from lymphopenia to innate and cellular immune dysfunction. Much work has been done to uncover a variety of tumor-inducible mechanisms for limiting the antitumor immune response. In this chapter, we will explore the evolution of our understanding of these immune-restricting mechanisms, as well as strategies for their reversal.
Duke Scholars
Citation
APA
Chicago
ICMJE
MLA
NLM
Berry-Candelario, J., Farber, S. H., & Fecci, P. E. (2017). Immune Constitution of Patients with Brain Tumors. In Translational Immunotherapy of Brain Tumors (pp. 13–32). https://doi.org/10.1016/B978-0-12-802420-1.00002-8
Berry-Candelario, J., S. H. Farber, and P. E. Fecci. “Immune Constitution of Patients with Brain Tumors.” In Translational Immunotherapy of Brain Tumors, 13–32, 2017. https://doi.org/10.1016/B978-0-12-802420-1.00002-8.
Berry-Candelario J, Farber SH, Fecci PE. Immune Constitution of Patients with Brain Tumors. In: Translational Immunotherapy of Brain Tumors. 2017. p. 13–32.
Berry-Candelario, J., et al. “Immune Constitution of Patients with Brain Tumors.” Translational Immunotherapy of Brain Tumors, 2017, pp. 13–32. Scopus, doi:10.1016/B978-0-12-802420-1.00002-8.
Berry-Candelario J, Farber SH, Fecci PE. Immune Constitution of Patients with Brain Tumors. Translational Immunotherapy of Brain Tumors. 2017. p. 13–32.